LBBW VC

LBBW Venture Capital GmbH is the investment arm of Landesbank Baden-Württemberg, established in 1998 and located in Stuttgart, Germany. The firm specializes in financing early to late-stage growth companies, particularly in the sectors of industrial technologies, information technology, software, telecommunications, innovative services, and life sciences. LBBW VC primarily targets investments in Southern Germany but is open to opportunities throughout Germany, Austria, and Switzerland. It typically invests between €0.5 million and €1.5 million per company, with the potential to contribute up to €5 million across multiple financing rounds. The firm takes an active role in its investments, often seeking advisory or supervisory board positions for larger stakes. LBBW VC has a strong international track record, having invested in over 60 companies, and typically exits investments within two to five years through trade sales or initial public offerings. The team boasts a history that includes two IPOs and the backing of one unicorn.

Julian Hebler

Investment Manager

Patrick Herlinger

Investment Manager

39 past transactions

specter automation

Seed Round in 2025
Specter Automation is a business-to-business software-as-a-service company focused on revolutionizing construction site management through artificial intelligence-powered automation. Acknowledging that the construction sector is one of the least digitized industries, Specter offers a web-based platform that integrates core components of construction planning with advanced tracking capabilities. By transforming existing digital planning data into a three-dimensional lookahead management system, the company enables construction firms and small to mid-sized enterprises to effectively utilize this data on-site. Specter’s software streamlines construction management processes, reduces organizational effort, and addresses inefficiencies, thereby significantly minimizing construction delays. Through its innovative approach, Specter aims to digitize the essential operations of construction projects, ensuring all stakeholders have access to relevant data while highlighting potential planning errors.

Metergrid

Seed Round in 2025
Metergrid develops software as a service for decentralized energy systems and provides an automated cloud platform to enable solar projects. It focuses on tenant electricity, enabling owners of multi-family and commercial properties to supply tenants with locally generated photovoltaic electricity. The company covers profitability analysis, project design and implementation, and billing software and hardware, supporting the transition to solar energy and offering end-to-end energy services for property owners and operators. By integrating project management with energy services, Metergrid aims to reduce electricity costs, improve property value, and advance a decentralized, sustainable energy future.

Leon Nanodrugs

Series D in 2024
Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

Impossible Cloud

Funding Round in 2024
Impossible Cloud is a pioneering decentralized cloud platform that harnesses web3 technology to deliver enterprise-grade multi-service cloud solutions. By offering faster, more affordable, and secure alternatives to traditional hyperscalers and private clouds, it focuses on providing businesses with a comprehensive suite of services tailored to meet their needs. The platform facilitates unlimited storage capacity and ensures 100% durability and availability, all without hidden costs or the necessity for cryptocurrency transactions. Its fiat-based payment system caters specifically to B2B customers, streamlining the financial aspect of cloud services. Furthermore, Impossible Cloud connects users to a global network of enterprise-grade storage hubs, which enhances performance and efficiency by reducing latency and optimizing data access near the customer's location.

AIPERIA

Series A in 2024
AIPERIA is a German-based company that specializes in providing a software-as-a-service (SaaS) solution aimed at enhancing sustainability in the fresh food supply chain. The company has developed an artificial intelligence-driven platform that facilitates end-to-end demand planning for suppliers and retailers. This platform allows for integrated and fully automated planning processes, ensuring that food production aligns closely with actual demand. By enabling suppliers to accurately forecast and deliver only the necessary quantities to retailers, AIPERIA contributes to reducing food waste and promoting more sustainable practices in the food retail sector.

Threedy

Series A in 2024
Threedy GmbH is a German company founded in 2020, specializing in high-performance visual computing solutions through its instant3Dhub platform. The platform is designed to support visualization, virtual reality, and augmented reality applications, primarily targeting the automotive, aerospace, and energy sectors. Threedy's technology allows for the seamless integration of large data sets with business data and sensors, facilitating a wide range of applications across different devices. Its features include a 3D streaming architecture and built-in 3D Spaces, which enable users to share context and data links effectively. By leveraging 3D data models, Threedy aims to drive digital innovation in products, services, and business processes, ultimately simplifying operations and reducing costs for its clients.

Bluu Seafood

Series A in 2023
Bluu Seafood is a biotechnology company focused on developing and commercially producing cultivated seafood made from fish cells. The company aims to offer nutritious fish products that are healthier and more sustainable by growing seafood in controlled environments, reducing reliance on traditional fishing and minimizing harm to animals and vulnerable ocean ecosystems. Through food technology, Bluu Seafood seeks to bring cultured fish products to the market for consumers seeking sustainable choices.

Oska Health

Pre Seed Round in 2023
Oska Health is a company focused on delivering digital care solutions for patients with chronic kidney disease, addressing a significant clinical need in healthcare. By utilizing evidence-based medical practices and insights from behavioral science, Oska Health empowers individuals to reduce their risk of cardiovascular complications and kidney failure while also minimizing care costs. The company collaborates with healthcare payers to provide a holistic approach that includes a personal coach, an advanced health application, and intelligent treatment plan algorithms. This comprehensive solution aims to support patients in establishing healthier routines and achieving better health outcomes by addressing their physical, emotional, and social needs with empathy and understanding.

specter automation

Seed Round in 2023
Specter Automation is a business-to-business software-as-a-service company focused on revolutionizing construction site management through artificial intelligence-powered automation. Acknowledging that the construction sector is one of the least digitized industries, Specter offers a web-based platform that integrates core components of construction planning with advanced tracking capabilities. By transforming existing digital planning data into a three-dimensional lookahead management system, the company enables construction firms and small to mid-sized enterprises to effectively utilize this data on-site. Specter’s software streamlines construction management processes, reduces organizational effort, and addresses inefficiencies, thereby significantly minimizing construction delays. Through its innovative approach, Specter aims to digitize the essential operations of construction projects, ensuring all stakeholders have access to relevant data while highlighting potential planning errors.

Code Intelligence

Series A in 2022
Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in developing advanced security software for application developers. The company offers an automated application security testing platform that employs coverage-based fuzzing and symbolic code execution to help identify and rectify security vulnerabilities in code. By automating various software attack simulations, Code Intelligence enables organizations to implement continuous security testing, significantly reducing the level of expert knowledge required for setup. Their solutions are designed to enhance the reliability and security of software, serving a diverse clientele that includes major global corporations such as Bosch, Deutsche Börse Group, and Deutsche Telekom.

Cedalo

Seed Round in 2022
Cedalo is an innovative software startup that provides a no-code platform aimed at enabling non-programmers to create and orchestrate applications and microservices for the Internet of Things (IoT). The company's platform focuses on intuitive operation and a user-friendly modeling environment, allowing users to develop real-time stream processing applications without needing extensive technical knowledge. Cedalo's offerings include features for visualizing, analyzing, simulating, and controlling IoT devices, as well as facilitating real-time data processing and analysis. By simplifying the development of individual apps and services, Cedalo aims to empower users to manage and control data streams effectively, meeting the demands of complex processes and high usage loads.

Exciva

Series A in 2021
Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing innovative therapies for dementia and related diseases. The company operates a targeted drug rescue program aimed at pharmaceutical research and development, specifically designed to create symptomatic and disease-modifying treatments. Exciva specializes in addressing both the neurological and psychological aspects of behavioral and psychological symptoms associated with dementia. Its approach involves rescuing and repurposing approved drugs for new indications and uses, thereby providing valuable solutions to the healthcare industry. Through its comprehensive program, Exciva seeks to improve treatment options and outcomes for patients suffering from dementia.

3YOURMIND

Series A in 2021
3YOURMIND GmbH is a Berlin-based company founded in 2013, specializing in the development of an industrial 3D printing software platform. With additional offices in San Francisco and Wroclaw, the company offers enterprise software solutions that automate additive manufacturing processes and workflows for leading firms and 3D print services. Its product suite standardizes various aspects of the additive manufacturing supply chain, including historical part data analysis, order management, and production scheduling. The software facilitates digital workflows, enabling data-driven production decisions while optimizing execution and quality assurance in distributed manufacturing. 3YOURMIND's tools, including Agile PLM and Agile ERP, enhance product innovation and streamline order processing. The company's expertise in additive manufacturing services supports clients throughout the entire workflow, from concept development to project execution. Notable clients include GKN, DB Schenker, and EOS, reflecting the company's commitment to advancing automated agile manufacturing solutions.

Actitrexx

Series A in 2021
ActiTrexx GmbH is a biotech start-up specializing in cellular therapy aimed at preventing inflammatory reactions associated with conditions such as graft-versus-host disease (GVHD), solid organ transplantation, and autoimmune diseases. The company has developed ATREGA, a treatment option specifically designed for patients who have undergone stem cell transplants, which significantly enhances survival rates by reducing the risk of transplant rejection. ActiTrexx focuses on advancing clinical testing of its cell therapeutics to address transplant rejection and autoimmunity, ultimately improving patients' quality of life and expanding therapeutic options in the field of transplantation medicine.

Code Intelligence

Series A in 2020
Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in developing advanced security software for application developers. The company offers an automated application security testing platform that employs coverage-based fuzzing and symbolic code execution to help identify and rectify security vulnerabilities in code. By automating various software attack simulations, Code Intelligence enables organizations to implement continuous security testing, significantly reducing the level of expert knowledge required for setup. Their solutions are designed to enhance the reliability and security of software, serving a diverse clientele that includes major global corporations such as Bosch, Deutsche Börse Group, and Deutsche Telekom.

Teralytics

Series D in 2019
Teralytics is a company specializing in mobility analytics, providing deep insights into human mobility needs through the use of big data and advanced machine learning. The company's platform is designed to optimize transportation planning and operations, helping clients address significant mobility challenges. Teralytics aims to transform how journeys are planned and managed, focusing on improving journey times, ensuring accessibility, enhancing operational efficiencies, and minimizing environmental impact. By delivering actionable insights, Teralytics supports the development of sustainable mobility solutions that cater to the needs of individuals and communities both now and in the future.

tado°

Secondary Market in 2018
tado° GmbH is a technology company based in Munich, Germany, with an additional office in London, United Kingdom. Founded in 2010, it specializes in developing and marketing innovative home climate control systems that enhance the efficiency of heating and cooling in residential and small business environments. The company's products integrate a hardware-software combination that leverages real-time data on resident behavior, weather forecasts, and building characteristics to optimize climate management. tado° sells its solutions through both retail outlets and online platforms, effectively bringing Internet of Things technology to the cleantech market.

Acousia Therapeutics

Series B in 2018
Acousia Therapeutics GmbH is a biotechnology company based in Tübingen, Germany, focused on developing innovative treatments for hearing loss. Established in 2012, the company specializes in identifying small molecules that can be applied locally to protect or restore hearing function. Acousia's approach centers on stimulating the regeneration of sensory hair cells in the inner ear, which are crucial for hearing. This regenerative capability is achieved by leveraging supporting cells that can replace lost hair cells. The company's therapeutic candidates aim to address hearing loss caused by various factors, such as noise exposure, ototoxic medication, and sudden deafness, and also hold potential for treating age-related hearing decline.

otego

Seed Round in 2018
otego GmbH is a German company founded in 2016 and headquartered in Karlsruhe. It specializes in the development of thermoelectric generators (TEGs) that provide independent energy solutions for wireless sensors and actuators. By converting heat directly into electric power through temperature differences, otego's technology is applicable in various fields, including the Internet of Things, waste heat recovery, and Industry 4.0. The company emerged as a spin-off from the Karlsruhe Institute of Technology and is driven by a diverse team comprising physicians, a chemist, and a business engineer, all dedicated to advancing and commercializing its innovative technology.

Crealytics

Series C in 2017
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

Amcure

Series B in 2016
Amcure GmbH is a clinical-stage biopharmaceutical company based in Eggenstein-Leopoldshafen, Germany, focused on the research and development of peptide-based compounds aimed at treating highly metastatic forms of squamous cancer. Founded in 2011 as a spin-off from the Karlsruhe Institute of Technology, Amcure leverages its expertise in CD44 target biology to develop innovative therapeutic approaches. Its lead compound, AM001, is a first-in-class CD44v6 inhibitor that disrupts key receptor tyrosine kinase pathways, including the VEGF/VEGF-R and HGF/c-Met pathways. This advancement is particularly relevant for treating various cancers such as pancreatic, head and neck, gastric, colorectal, breast, and lung cancers. Amcure's commitment to addressing the challenges of metastatic cancer is underscored by its clinical development efforts, which began in late 2016.

CorTec

Series B in 2016
CorTec is a developer and manufacturer specializing in medical device components and active implantable systems for neuromodulation applications and brain-computer interfaces. With a decade of intensive research and development, the company has created the CorTec Brain Interchange System, a unique platform technology designed to facilitate the development of novel therapies for neurological diseases. This system features laser-structured AirRay electrode arrays that provide a reliable and flexible interface for permanent brain recordings, gently conforming to the brain's curvature. A biocompatible ceramic encapsulation houses an electronics unit that preprocesses data, while a custom-developed microchip amplifies neuronal signals across multiple channels and digitizes them at a high sampling rate. The system operates without a battery, utilizing an inductive power supply to eliminate the need for surgical replacements. Additionally, CorTec supports Medtech companies and startups in neurotechnology by providing components and services related to the Brain Interchange System.

Enoware

Seed Round in 2015
Enoware specializes in mobile sensor systems designed for the geothermal energy sector. The company offers a miniaturized geothermal measuring capsule that enhances the efficiency and quality of geothermal probes. Its technology allows users to access vital environmental data through an online portal and smartphone application, facilitating system monitoring, optimization, and operational safety. With over 300,000 geothermal probes currently in operation in Germany and an annual addition of 20,000 new systems, Enoware is positioned to expand its customer base and contribute to the growing demand for sustainable energy solutions.

Biametrics

Series A in 2015
Biametrics is a company that specializes in providing advanced research and development services tailored for the academia, pharmaceutical, biotechnology, and diagnostic sectors. Its products focus on label-free detection systems that characterize biomolecular interactions by delivering critical kinetic and affinity data, as well as thermodynamic information such as enthalpy and entropy. By employing innovative technological methods, Biametrics enhances the capabilities of its clients in data evaluation, facilitating applications that range from diagnostics to process analytics. The company's solutions are designed to offer unmatched performance in throughput and versatility, meeting the diverse needs of scientists in their research endeavors.

Amcure

Series A in 2014
Amcure GmbH is a clinical-stage biopharmaceutical company based in Eggenstein-Leopoldshafen, Germany, focused on the research and development of peptide-based compounds aimed at treating highly metastatic forms of squamous cancer. Founded in 2011 as a spin-off from the Karlsruhe Institute of Technology, Amcure leverages its expertise in CD44 target biology to develop innovative therapeutic approaches. Its lead compound, AM001, is a first-in-class CD44v6 inhibitor that disrupts key receptor tyrosine kinase pathways, including the VEGF/VEGF-R and HGF/c-Met pathways. This advancement is particularly relevant for treating various cancers such as pancreatic, head and neck, gastric, colorectal, breast, and lung cancers. Amcure's commitment to addressing the challenges of metastatic cancer is underscored by its clinical development efforts, which began in late 2016.

Crealytics

Series B in 2014
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

PressMatrix

Series A in 2013
PressMatrix GmbH is a Berlin-based technology startup specializing in digital publishing services tailored for magazines, books, journals, and various customer documents. Founded in 2009 and initially known as bblabs UG, the company rebranded to PressMatrix GmbH in January 2011. Its offerings include a comprehensive publishing solution that features subscription services, mobile applications, and a platform for cross-channel distribution. PressMatrix serves a diverse clientele, including well-known publishers and agencies such as Georg Thieme Verlag and Carry-On Publishing GmbH. The company is dedicated to helping publishers effectively deliver their content on tablets and mobile devices, ensuring impactful engagement with their audiences.

Crealytics

Venture Round in 2013
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

Tocario

Seed Round in 2012
Tocario GmbH is a cloud IT company based in Stuttgart, Germany, founded in 2011. It specializes in developing a hosted virtual desktop solution that provides an automated, self-service platform for IT professionals to manage desktop infrastructure efficiently. Tocario offers its services as a fully automated Desktop-as-a-Service (DaaS) solution, catering to European end customers and white-label partners, as well as providing enterprise licenses to public and private cloud service providers. Its technology addresses various business needs by enhancing agility and reducing complexity, allowing users to deploy virtual desktop workplaces securely and without upfront investments. The solution is designed to function across all desktop devices and applications, even in low bandwidth scenarios. Recognized for its innovation in digital workspaces, Tocario has been acknowledged by industry analysts and partners, including NetApp and IBM, which positions it as a notable player in the evolving landscape of digital workspace solutions.

avandeo

Venture Round in 2012
avandeo, a Munich, Germany- and Shanghai, China-based startup that operates an online destination for designer furniture and home accessories.

CargoGuard

Venture Round in 2011
CargoGuard GmbH is a company based in Merseburg, Germany, founded in 2007, that specializes in security and transparency solutions for logistics. It develops advanced systems designed to protect valuable goods, high-end products, and sensitive documents from risks such as loss, theft, and manipulation during transportation and storage. CargoGuard offers a range of services including portable tracking, secure monitoring of valuables, fixed tracking, and Internet-of-Things-Lock solutions. Their cloud-based security monitoring system enhances the safeguarding of valuable goods across the intermodal supply chain, serving a diverse clientele that includes cash and valuables transport companies, logistics providers, automotive industries, and various sectors in manufacturing and insurance. By integrating locking and sealing functions with GPS tracking and condition monitoring, CargoGuard enables businesses to effectively manage and secure their valuable transports worldwide.

Crealytics

Venture Round in 2011
Crealytics is a performance marketing agency that specializes in the retail sector, focusing on digital advertising across platforms such as Google, Bing, Amazon, Pinterest, and Facebook. With a team of over 150 professionals, Crealytics challenges traditional assumptions in digital marketing by integrating marketing with merchandising and pricing strategies. This approach allows retailers to optimize their ad investments for maximum profitability and Customer Lifetime Value. The company's proprietary technology, supported by an in-house team of data scientists, automates the creation and optimization of customized advertisements, streamlining campaign management and enhancing strategic decision-making. Crealytics operates globally, delivering paid search campaigns in 150 markets and 20 languages, with offices located in London, New York, and Berlin.

Intelligent Fluid

Series B in 2011
Intelligent fluids GmbH is a technology company specializing in the development of innovative high-performance cleaning fluids that utilize patented technology to create unique, eco-friendly solutions. These fluids are designed to meet specific cleaning needs while ensuring safety for users, equipment, and the environment, distinguishing them from traditional solvent-based chemicals. They are particularly effective in various sectors such as microelectronics, industrial maintenance, optics, and the printing industry, where they facilitate processes like stripping, material separation, and cleaning of contaminants. Intelligent fluids GmbH also engages in joint development and private label agreements to create tailored products. With a strong emphasis on sustainability, the company's offerings support multiple United Nations Sustainable Development Goals by significantly reducing carbon emissions, energy costs, and material consumption, while promoting efficiency and effectiveness in cleaning operations.

Phenex Pharmaceuticals

Series C in 2010
Phenex Pharmaceuticals AG is a privately held drug discovery and development company based in Ludwigshafen, Germany, with additional facilities in Heidelberg. Founded in 2002, the company specializes in small-molecule drug discovery, focusing on liver diseases, intestinal diseases, and cancer. Its research includes developing retinoid-acid receptor-related orphan receptor gamma t (RORγt) inverse agonists for autoimmune diseases and farnesoid X receptor (FXR) agonists for non-alcoholic steatohepatitis. Phenex aims to identify novel molecular mechanisms and develop innovative therapeutics, having already translated two such mechanisms into proprietary small molecules.

MTM Laboratories

Series C in 2009
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.

Sloning BioTechnology

Venture Round in 2009
Sloning BioTechnology specializes in the production of high-quality, customized DNA molecules at an industrial scale. Its proprietary Slonomics technology platform enables reliable and cost-effective synthesis, overcoming traditional sequence limitations through a fully-automated robotic system. Additionally, the company offers synthetic biology tools to support its clients' research and development efforts.

Oxid eSales

Venture Round in 2008
OXID eSales AG is a prominent provider of multi-channel e-commerce solutions based in Freiburg, Germany, with an additional office in Halle. Founded in 2003, the company specializes in developing open-source shopping cart software, notably the OXID eShop platform. This platform caters to both B2B and B2C markets, offering scalable and customizable solutions that enhance online shopping experiences. OXID eSales serves a diverse clientele, including major brands like Lekkerland, Strenesse, Intersport, Gravis, and Deutsche Post, who benefit from the company’s extensive network of certified solution partners and dedicated support teams. The company's offerings also include the OXID eFire e-commerce intelligence platform, which streamlines online marketing, payment services, and intelligent search through a unified user interface. With a focus on innovation and quality, OXID eSales positions itself as a reliable partner for medium-sized businesses seeking to digitalize their sales processes and expand their market reach.

Phenex Pharmaceuticals

Series B in 2008
Phenex Pharmaceuticals AG is a privately held drug discovery and development company based in Ludwigshafen, Germany, with additional facilities in Heidelberg. Founded in 2002, the company specializes in small-molecule drug discovery, focusing on liver diseases, intestinal diseases, and cancer. Its research includes developing retinoid-acid receptor-related orphan receptor gamma t (RORγt) inverse agonists for autoimmune diseases and farnesoid X receptor (FXR) agonists for non-alcoholic steatohepatitis. Phenex aims to identify novel molecular mechanisms and develop innovative therapeutics, having already translated two such mechanisms into proprietary small molecules.

Sloning BioTechnology

Series E in 2007
Sloning BioTechnology specializes in the production of high-quality, customized DNA molecules at an industrial scale. Its proprietary Slonomics technology platform enables reliable and cost-effective synthesis, overcoming traditional sequence limitations through a fully-automated robotic system. Additionally, the company offers synthetic biology tools to support its clients' research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.